Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

S.J.A.M. Santegoets, A.G.M. Stam, S.M. Lougheed, H. Gall, K. Jooss, N. Sacks, K. Hege, I. Lowy, R.J. Scheper, W.R. Gerritsen, A.J.M. van den Eertwegh, T.D. de Gruijl

Research output: Contribution to journalArticleAcademicpeer-review

89 Citations (Scopus)
Original languageUndefined/Unknown
Article number31
JournalJournal for Immunotherapy of Cancer
Publication statusPublished - 2014

Cite this